
Halobet0.05%
Square Pharmaceuticals PLC.
Established / FDA-Approved Uses Halobetasol Propionate cream, ointment, and lotion (0.05%) are indicated for the short-term topical treatment (typically no more than 2 consecutive weeks) of…
Halobetasol Propionate is not indicated for widespread plaque psoriasis, and is not a first-line agent for mild dermatoses.
| Formulation | Application | Maximum Duration | Maximum Weekly Quantity |
|---|---|---|---|
| Cream / Ointment 0.05% | Apply a thin layer to the affected skin once or twice daily; rub in gently and completely | 2 consecutive weeks | Not to exceed 50 g/week |
| Lotion 0.05% | Apply a thin layer to the affected skin twice daily | 2 consecutive weeks | Not to exceed 50 g (or 50 mL)/week |
| Lotion 0.01% (lower-strength product) | Apply a thin film to the affected skin once daily | Per specific product labeling, generally up to 8 weeks under close supervision | Per specific product labeling |
Treatment should be discontinued when control is achieved. If no improvement is seen within 2 weeks, the diagnosis should be reassessed. The total treated body surface area should not exceed approximately 20% at any time. Halobetasol Propionate should not be used with occlusive dressings unless specifically directed by a physician.
Safety and efficacy of Halobetasol Propionate 0.05% products have not been established in patients younger than 18 years; use in this age group is not recommended. See Pediatric Uses for further detail.
No specific dosage adjustment of topical Halobetasol Propionate is established for renal or hepatic impairment, since systemic exposure from correctly used topical therapy is expected to be low; however, caution and closer monitoring for systemic corticosteroid effects are reasonable if impairment is significant, as clearance of any absorbed drug may be reduced.
Excessive or prolonged use of Halobetasol Propionate, especially over large areas or under occlusion, can lead to reversible hypothalamic-pituitary-adrenal (HPA)-axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria; these usually resolve upon discontinuation. See Precautions and Warnings.
Halobetasol Propionate is contraindicated in patients with known hypersensitivity to Halobetasol Propionate or to any other component of the specific cream, ointment, or lotion formulation being used.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.